Meditor Group Ltd Exits Position in Inotek Pharmaceuticals Corp (ITEK)

Inotek Pharmaceuticals Corp (ITEK) : Meditor Group Ltd has sold out all of its stake in Inotek Pharmaceuticals Corp during the most recent quarter, according to the disclosure filed by the company on Apr 18, 2016 with the SEC. The investment management company has sold out 12,594 shares of Inotek Pharmaceuticals Corp which is valued at $115,613.

Inotek Pharmaceuticals Corp closed down -0.15 points or -1.61% at $9.18 with 56,258 shares getting traded on Friday. Post opening the session at $9.4, the shares hit an intraday low of $9.0501 and an intraday high of $9.68 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Acadian Asset Management sold out all of its stake in ITEK during the most recent quarter. The investment firm sold 40,827 shares of ITEK which is valued $376,017.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Company’s business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery development and commercialization of therapies for glaucoma. Its lead product candidate trabodenoson is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company’s product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).

Leave a Reply

Inotek Pharmaceuticals Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Inotek Pharmaceuticals Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.